Jing Wu, M.D.
National Cancer Institute (NCI)
5
5
1
N/A
0
9
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (5)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Sabine Mueller, MD, PhD, MAS
University of California, San Francisco
Shared therapeutic areas:
Steven Chmura, MD
University of Chicago
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
Giselle Sholler, MD
Beat Childhood Cancer at Atrium Health
Shared therapeutic areas:
Kevin A camphausen, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
Maryam Fouladi, MD
Nationwide Children's Hospital
Shared therapeutic areas:
Gustavo Leone
Medical University of South Carolina, Hollings Cancer Center
Shared therapeutic areas:
Amar Gajjar, MD
St. Jude Children's Research Hospital
Shared therapeutic areas:
Worked with same sponsors:
Jeffrey Raizer, MD
Northwestern University
Shared therapeutic areas:
Worked with same sponsors:
Adam Mamelak, MD
Cedars-Sinai Medical Center
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (5)
Showing 5 of 5 trials
Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
All 5 trials loaded